Kestra Medical Technologies filings document the public-company disclosures of a Bermuda-incorporated medical technology issuer listed on Nasdaq under KMTS. Its Form 8-K reports have furnished quarterly and annual financial results, revenue guidance, and Regulation FD disclosures tied to the ASSURE WCD and ACE-PAS post-approval study results.
The company’s proxy materials and annual meeting filings cover board elections, independent auditor ratification, shareholder voting results, and equity compensation matters, including the 2025 Employee Stock Purchase Plan. These records also identify governance procedures and formal shareholder actions for the wearable defibrillator and digital health business.
Kestra Medical Technologies director and officer Brian Daniel Webster sold a total of 15,000 Common Shares of KMTS in open-market transactions on February 17, 2026. The sales occurred under a pre-arranged Rule 10b5-1 trading plan adopted on September 29, 2025.
The transactions were executed in three tranches: 11,635 shares at a weighted average price of $25.3937, 3,272 shares at $26.2947, and 93 shares at $27.1789. After these sales, Webster directly held 379,786 Common Shares.
Bain Charger Holdings, L.P., an affiliate of Bain Capital, reports a significant ownership position in Kestra Medical Technologies, Ltd. common shares. As of the close of business on December 31, 2025, Bain Charger directly held 25,172,338 common shares.
These holdings represent approximately 43.1% of Kestra’s outstanding common shares, based on 58,349,053 shares outstanding as of December 5, 2025, as cited from Kestra’s Form 10-Q. Bain Charger and its general partner share voting and dispositive power over these shares.
Kestra Medical Technologies shareholder Brian Webster has filed a Form 144 notice to sell 15,000 common shares. The proposed sale is through Merrill Lynch on NASDAQ, with an aggregate market value of $384,020.06, and an approximate sale date of February 17, 2026.
The 15,000 shares were acquired on March 7, 2025 via a restricted share issuance granted under the issuer’s equity compensation plan. Over the past three months, Webster sold 15,000 common shares on December 29, 2025 for $398,847.04 and another 15,000 shares on January 15, 2026 for $342,023.69.
Endeavour Medtech Growth II LP, Endeavour Medtech Growth II Parallel LP, and Endeavour Medtech II GP Limited report beneficial ownership of 2,448,942 Kestra Medical Technologies common shares, representing 4.20% of the class.
The filing explains that 2,405,643 shares are held by Endeavour Medtech Growth II LP and 43,299 shares by Endeavour Medtech Growth II Parallel LP, with Endeavour Medtech II GP Limited as general partner for both. All reported shares are subject to shared voting and dispositive power, with no sole voting or dispositive authority. The 4.20% figure is based on 58,349,053 common shares outstanding as of December 5, 2025.
T. Rowe Price Associates, Inc. filed a Schedule 13G reporting a significant passive ownership position in Kestra Medical Technologies common stock. As of 12/31/2025, it reported beneficial ownership of 4,369,429 shares, representing 7.5% of the outstanding common stock.
The firm reports sole voting power over 4,208,056 shares and sole dispositive power over all 4,369,429 shares, with no shared voting or dispositive power. T. Rowe Price certifies the shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Kestra, and expressly denies beneficial ownership in a legal-admission sense.
Kestra Medical Technologies president, chief executive officer and director Brian Daniel Webster reported selling 15,000 common shares of KMTS on January 15, 2026. The sale was coded as an open-market sale and was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on September 29, 2025, indicating it was scheduled in advance. The shares were sold at a weighted average price of $22.8016, with individual sale prices ranging from $22.2800 to $23.1340. After this transaction, Webster beneficially owns 394,786 common shares, held directly.
This Form 144 notice reports a planned sale of restricted common shares of Kestra Medical Technologies, Ltd. The seller intends to sell 15,000 common shares through Merrill Lynch on the NASDAQ, with an indicated aggregate market value of $342,023.69. The shares form part of a larger base of 58,349,053 common shares outstanding.
The securities were originally acquired on 03/07/2025 as a restricted share issuance from Kestra Medical Technologies, Ltd., granted under the issuer’s equity compensation plan. The notice also shows that Brian Webster sold 15,000 common shares on 12/29/2025 for gross proceeds of $398,847.04. By signing the notice, the seller represents that they are not aware of any undisclosed material adverse information about the company.
Kestra Medical Technologies, Ltd. filed a current report stating that it issued a press release announcing its financial results for the fiscal quarter ended October 31, 2025.
The press release, dated December 11, 2025, is attached as Exhibit 99.1, is incorporated by reference into this report, and is furnished rather than filed, so it is not automatically incorporated into other securities filings unless specifically referenced.
Kestra Medical Technologies (KMTS) disclosed an initial ownership filing on Form 3 for officer Timothy P. Moran, who serves as Chief Business Officer. The filing states “No securities are beneficially owned.” The date of event is 11/03/2025. This is an administrative disclosure under Section 16 reporting Mr. Moran’s starting beneficial ownership status with the company.
Kestra Medical Technologies (KMTS) filed an 8‑K under Regulation FD, furnishing a press release titled “Largest Real-World Study of Wearable Defibrillators Confirms Strong Effectiveness and Safety Performance of Kestra’s ASSURE Device.” The release announces primary results from the ACE‑PAS post‑approval study, presented as late‑breaking science at the American Heart Association Scientific Sessions 2025 in New Orleans.
The press release is furnished as Exhibit 99.1 and, as noted, is not deemed “filed” for Section 18 liability purposes or incorporated by reference unless specifically stated. The filing includes customary forward‑looking statements language and directs readers to risk factors in the company’s Form 10‑K for the fiscal year ended April 30, 2025.